SC notice to Centre on providing drugs at affordable price

A bench headed by Justice G S Singhvi asked the Centre to file its reply to the PIL which said a model devised by AIIMS, under which it provides medicines and surgical items at 56 percent discount on Maximum Retail Price (MRP), should be adopted by all government hospitals.

"It is most respectfully and humbly prayed that the court issue appropriate direction to all government owned and aided health care establishments to incorporate a model devised and implemented by the All India Institute of Medical Sciences which ensures that medicines and surgical items and other such items are made available at 56 percent discount on MRP," the petitioner Avinash Goenka said.

He submitted the cost of manufacturing a drug is relatively low but medicines are being sold at inflated prices which needs to be curbed.

"In pharmaceuticals sector, the cost of manufacturing a drug is relatively low, compared to the price it is sold at. By selling drugs at inflated prices, big companies and retailers pocket a large unjustified share of the money, paid by the consumer," he said in his petition.

"There are abnormally high trade margins with wasteful, unregulated and unethical drug promotion. There is a nexus between drug companies, stockists, retailers, medical representatives and some medical practitioners which disproportionately inflates the cost of medicines and overall treatment," the petition said.

  

image
Business Standard
177 22
Business Standard

SC notice to Centre on providing drugs at affordable price

Press Trust of India  |  New Delhi 



A bench headed by Justice G S Singhvi asked the Centre to file its reply to the PIL which said a model devised by AIIMS, under which it provides medicines and surgical items at 56 percent discount on Maximum Retail Price (MRP), should be adopted by all government hospitals.

"It is most respectfully and humbly prayed that the court issue appropriate direction to all government owned and aided health care establishments to incorporate a model devised and implemented by the All India Institute of Medical Sciences which ensures that medicines and surgical items and other such items are made available at 56 percent discount on MRP," the petitioner Avinash Goenka said.

He submitted the cost of manufacturing a drug is relatively low but medicines are being sold at inflated prices which needs to be curbed.

"In pharmaceuticals sector, the cost of manufacturing a drug is relatively low, compared to the price it is sold at. By selling drugs at inflated prices, big companies and retailers pocket a large unjustified share of the money, paid by the consumer," he said in his petition.

"There are abnormally high trade margins with wasteful, unregulated and unethical drug promotion. There is a nexus between drug companies, stockists, retailers, medical representatives and some medical practitioners which disproportionately inflates the cost of medicines and overall treatment," the petition said.

  

RECOMMENDED FOR YOU

SC notice to Centre on providing drugs at affordable price

The Supreme Court today sought the Centre's reply to a plea for its direction to it put in place a mechanism at health care centres to provide medicines to patients at affordable price.

A bench headed by Justice G S Singhvi asked the Centre to file its reply to the PIL which said a model devised by AIIMS, under which it provides medicines and surgical items at 56 percent discount on Maximum Retail Price (MRP), should be adopted by all government hospitals.

"It is most respectfully and humbly prayed that the court issue appropriate direction to all government owned and aided health care establishments to incorporate a model devised and implemented by the All India Institute of Medical Sciences which ensures that medicines and surgical items and other such items are made available at 56 percent discount on MRP," the petitioner Avinash Goenka said.

He submitted the cost of manufacturing a drug is relatively low but medicines are being sold at inflated prices which needs to be curbed.

"In pharmaceuticals sector, the cost of manufacturing a drug is relatively low, compared to the price it is sold at. By selling drugs at inflated prices, big companies and retailers pocket a large unjustified share of the money, paid by the consumer," he said in his petition.

"There are abnormally high trade margins with wasteful, unregulated and unethical drug promotion. There is a nexus between drug companies, stockists, retailers, medical representatives and some medical practitioners which disproportionately inflates the cost of medicines and overall treatment," the petition said.

  
image
Business Standard
177 22

More News

  • Signs of realty revival ahead of festive season Signs of realty revival ahead of festive season
  • Amit Chandra Bain Capital's Amit Chandra joins Tata Sons board
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard